全文获取类型
收费全文 | 345篇 |
免费 | 18篇 |
国内免费 | 18篇 |
专业分类
儿科学 | 50篇 |
妇产科学 | 2篇 |
基础医学 | 14篇 |
口腔科学 | 1篇 |
临床医学 | 25篇 |
内科学 | 59篇 |
皮肤病学 | 3篇 |
神经病学 | 1篇 |
特种医学 | 86篇 |
外科学 | 74篇 |
综合类 | 11篇 |
预防医学 | 17篇 |
眼科学 | 1篇 |
药学 | 23篇 |
1篇 | |
肿瘤学 | 13篇 |
出版年
2023年 | 1篇 |
2021年 | 1篇 |
2019年 | 10篇 |
2018年 | 8篇 |
2017年 | 3篇 |
2016年 | 3篇 |
2015年 | 8篇 |
2014年 | 12篇 |
2013年 | 14篇 |
2012年 | 18篇 |
2011年 | 19篇 |
2010年 | 12篇 |
2009年 | 12篇 |
2008年 | 17篇 |
2007年 | 22篇 |
2006年 | 11篇 |
2005年 | 11篇 |
2004年 | 11篇 |
2003年 | 16篇 |
2002年 | 6篇 |
2001年 | 13篇 |
2000年 | 25篇 |
1999年 | 4篇 |
1998年 | 16篇 |
1997年 | 10篇 |
1996年 | 5篇 |
1995年 | 5篇 |
1994年 | 7篇 |
1993年 | 6篇 |
1992年 | 6篇 |
1991年 | 2篇 |
1989年 | 7篇 |
1988年 | 9篇 |
1987年 | 8篇 |
1986年 | 7篇 |
1985年 | 6篇 |
1984年 | 3篇 |
1983年 | 7篇 |
1982年 | 1篇 |
1981年 | 3篇 |
1980年 | 5篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1976年 | 1篇 |
1975年 | 4篇 |
排序方式: 共有381条查询结果,搜索用时 46 毫秒
1.
2.
Spectrum of pulmonary nontuberculous mycobacterial infection 总被引:5,自引:0,他引:5
3.
4.
William T Mahle Robert N Vincent Alexandria M Berg Kirk R Kanter 《The Journal of heart and lung transplantation》2005,24(1):63-66
BACKGROUND: Hydroxymethylglutaryl CoA reductase inhibitors (statins) have been demonstrated to reduce the risk of developing coronary allograft vasculopathy (CAV) following heart transplantation in adults and are used routinely in many centers. CAV and lipid abnormalities have been reported to be less prevalent in pediatric heart transplant recipients. It is not known whether statins reduce the risk of CAV in this population METHODS: A retrospective review was performed to analyze the risk factors for developing CAV following pediatric heart transplantation with particular attention to the impact of pravastatin therapy. The study population was comprised of 129 pediatric patients who underwent 142 heart transplants at our institution from 1988 to 2003. The outcome variable was freedom from CAV, CAV being determined by coronary angiography or autopsy. RESULTS: CAV was identified in 25 recipients at a median of 3.7 years after transplantation. There were 331 patient-years of pravastatin therapy. Pravastatin therapy resulted in a reduction in total cholesterol levels, 162 +/- 29 to 137 +/- 20 mg/dl, p = 0.01. In multivariate analysis the use of pravastatin was associated with a lower incidence of CAV (p = 0.03), whereas an increased frequency of late rejection (p = 0.003) and earlier year of transplantation (p = 0.04) were associated with increased risk of CAV. CONCLUSIONS: The routine use of pravastatin was associated with a lower risk following pediatric heart transplantation. Further studies into the relationship between lipid abnormalities, inflammation and rejection, and the development of CAV in children are warranted. 相似文献
5.
Localization of a gene for otosclerosis to chromosome 15q25-q26 总被引:5,自引:0,他引:5
Tomek MS; Brown MR; Mani SR; Ramesh A; Srisailapathy CR; Coucke P; Zbar RI; Bell AM; McGuirt WT; Fukushima K; Willems PJ; Van Camp G; Smith RJ 《Human molecular genetics》1998,7(2):285-290
Among white adults otosclerosis is the single most common cause of hearing
impairment. Although the genetics of this disease are controversial, the
majority of studies indicate autosomal dominant inheritance with reduced
penetrance. We studied a large multi- generational family in which
otosclerosis has been inherited in an autosomal dominant pattern. Five of16
affected persons have surgically confirmed otosclerosis; the remaining nine
have a conductive hearing loss but have not undergone corrective surgery.
To locate the disease- causing gene we completed genetic linkage analysis
using short tandem repeat polymorphisms (STRPs) distributed over the entire
genome. Multipoint linkage analysis showed that only one genomic region, on
chromosome 15q, generated a lod score >2.0. Additional STRPs were typed
in this area, resulting in a lod score of 3.4. STRPs FES (centromeric) and
D15S657 (telomeric) flank the 14. 5 cM region that contains an otosclerosis
gene.
相似文献
6.
目的:研究L-门冬酰胺酶(L-Asparaginase,L-A)前体脂质体(Proliposome,PL)[L-APL]iv对小鼠的毒性及对荷瘤小鼠的抗肿瘤活性。方法:以小鼠的急性毒性和外周血中白细胞数及血小板数为指标观察药物对小鼠的毒性及以荷瘤小鼠的瘤重和生命延和工率观察药物的抗肿瘤活性;结果:L-APL iV对小鼠的急性毒性与L-A相比明显降低,L-APL对正常小鼠外周血中白细胞数,血小板数无明显影响,而相同剂量L-A对小鼠外周血中白细胞数,血小板数明显降低。与对照组相比,L-APL和L-Aip可明显延长腹水型小鼠移瘤L1210,P388的存活天数,与同剂量L-A相比,L-APL高剂量有明显延长腹水型小鼠移植瘤的存活天数作用。L-APL及L-A ip对小鼠移植瘤Heps,EC实体型的肿瘤生长具有明显的抑制作用,两者抑瘤作用相近。结论:L-APL对小鼠的毒性明显小于相同剂量的L-A,L-APL不仅保持了L-A的抗肿瘤活性,而且有明显的增效作用。 相似文献
7.
Michael WT Chao David Byram Richard Bell Rodney Bond Steven Vaughan Roger McLennan Michael Lim-Joon Morikatsu Wada David Joseph 《Journal of Medical Imaging and Radiation Oncology》1998,42(1):47-51
Postoperative combined modality therapy with radiotherapy and 5-fluorouracil (5FU) chemotherapy is an effective adjuvant approach that reduces locoregional and distant metastatic disease in patients with high-risk rectal carcinoma. However, this approach results in a treatment regimen of at least 6 months’duration. The present prospective study investigates the integration of radiotherapy and 5FU chemotherapy in a protocol designed to minimize toxicity and reduce the overall treatment time. A total of 40 patients with TNM stage II or III disease received postoperative radiotherapy at four fractions per week with weekly 5FU bolus injections delivered on the fifth non-radiotherapy day. Patients also received systemic chemotherapy with leucovorin both before and after pelvic irradiation, with the total treatment duration extending for only 18 weeks. Patients were able to complete radiotherapy in 90% of cases, while the delivery of full-dose chemotherapy was achievable in the vast majority. The incidence of haematologic and gastrointestinal toxicities requiring the cessation of treatment was acceptable. With a median follow-up of 20.9 months among surviving patients, the estimated progression-free and overall survival at 2 years were 71 % and 79%, respectively. 相似文献
8.
BS Marino PH Lipkin JW Newburger G Peacock M Gerdes JW Gaynor KA Mussatto K Uzark CS Goldberg WH Johnson J Li SE Smith DC Bellinger WT Mahle;on behalf of the American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young Council on Cardiovascular Nursing Stroke Council 《Circulation》2012,126(9):1143-1172
BACKGROUND: The goal of this statement was to review the available literature on surveillance, screening, evaluation, and management strategies and put forward a scientific statement that would comprehensively review the literature and create recommendations to optimize neurodevelopmental outcome in the pediatric congenital heart disease (CHD) population. METHODS AND RESULTS: A writing group appointed by the American Heart Association and American Academy of Pediatrics reviewed the available literature addressing developmental disorder and disability and developmental delay in the CHD population, with specific attention given to surveillance, screening, evaluation, and management strategies. MEDLINE and Google Scholar database searches from 1966 to 2011 were performed for English-language articles cross-referencing CHD with pertinent search terms. The reference lists of identified articles were also searched. The American College of Cardiology/American Heart Association classification of recommendations and levels of evidence for practice guidelines were used. A management algorithm was devised that stratified children with CHD on the basis of established risk factors. For those deemed to be at high risk for developmental disorder or disabilities or for developmental delay, formal, periodic developmental and medical evaluations are recommended. A CHD algorithm for surveillance, screening, evaluation, reevaluation, and management of developmental disorder or disability has been constructed to serve as a supplement to the 2006 American Academy of Pediatrics statement on developmental surveillance and screening. The proposed algorithm is designed to be carried out within the context of the medical home. This scientific statement is meant for medical providers within the medical home who care for patients with CHD. CONCLUSIONS: Children with CHD are at increased risk of developmental disorder or disabilities or developmental delay. Periodic developmental surveillance, screening, evaluation, and reevaluation throughout childhood may enhance identification of significant deficits, allowing for appropriate therapies and education to enhance later academic, behavioral, psychosocial, and adaptive functioning. 相似文献
9.
10.
Arthur J Richardson Jerome M Laurence Vincent WT Lam 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2014,16(1):12-19